|
|
| |
| Necrotizing External Otitis: Which Antibiotics Are Proposed: Report of 12 Cases
Download PDF
|
Chekh hammoud Z, Ouahidi Y, Belatik H, Hmidi M, touiheme N, Attifi H, Elboukhari A, Nadour K
|
Abstract:
Necrotizing otitis externa is a rare disease, difficult to diagnose, often dangerous It is an infection that occurs mainly on poor ground such as immunocompromised subjects, or most often elderly diabetic subjects. Pseudomonas aeruginosa is responsible for infection in 90% cases. Aim and methods: the main object is to discuss through a retrospective study of a series of 12 cases of malignant otitis externa collected at the ENT department of the HMMI in Meknes over a period of 6 years from January 2014 to December 2019, the therapeutic modalities of patients with necrotizing otitis externa in order to highlight the associations of antibiotic therapies recommended and to avoid therapeutic failures. The secondary objectives were to study the epidemiological, clinical, paraclinical, and evolutionary aspects of otitis externa malignancy. Results: The average age of our patients is 60 years; the sex ratio is 5 (10 men and 2 women). 83% of our patients were diabetic. The clinical picture was dominated by a severe and insomning otalgia. Purulent otorrhea was a reason for consultation in 67% of cases. Peripheral facial paralysis was noted in 2 cases (17%). Otoscopy showed stenosis and congestive ear canal with granulation tissue in all patients. Bacteriological sampling isolated Pseudomonas aeruginosa in 62.5% of cases. The CT scan was requested to confirm the diagnosis and to judge the extension. Patient monitoring is based on clinic, biology and radiology. All our patients have been hospitalized with daily local care, balanced diabetes and antibiotic treatment using mainly fluoroquinolones. Otitis evolution was favorable in 67% of cases. The recidivism rate was 8%. The attainment of cranial pairs was partially reversible under treatment in one patient. The prognosis of this pathology seems to be improved dramatically with the advent of new active molecules on Pseudomonas.
|
|
|
| | |